Nicole Collins, MD
Internal Medicine · Garner, NCNPI 1760419261
Payments from drug & device makers
Across 383 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- Amgen$933
- Lilly USA, LLC$737
- AbbVie$617
- Nevro Corp.$502
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,960100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $1,734 |
| Novo Nordisk | 85 | $1,696 |
| Amgen | 43 | $933 |
| Lilly USA, LLC | 35 | $737 |
| AbbVie | 32 | $617 |
| Nevro Corp. | 9 | $502 |
| GSK | 21 | $448 |
| Boehringer Ingelheim | 13 | $231 |
| Bayer | 10 | $224 |
| Merck | 5 | $178 |
| Otsuka America Pharmaceutical, Inc. | 8 | $171 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $170 |
| Sanofi-aventis U.S. LLC | 9 | $169 |
| Abbott | 2 | $153 |
| Astellas Pharma US Inc | 7 | $121 |
| Exact Sciences | 6 | $109 |
| Novartis | 7 | $108 |
| Urovant Sciences Inc | 1 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $78 |
| Medtronic(2 entities) | 4 | $74 |
| Mylan Specialty L.p. | 4 | $72 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $50 |
| Viatris Specialty LLC | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,993 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 256 | $293,090 |
| JardianceEmpagliflozin | 120 | $119,341 |
| EliquisApixaban | 150 | $117,697 |
| MounjaroTirzepatide | 99 | $107,257 |
| TrulicityDulaglutide | 69 | $91,238 |
| Enbrel SureclickEtanercept | 12 | $89,916 |
| FarxigaDapagliflozin Propanediol | 101 | $79,610 |
| LinzessLinaclotide | 112 | $74,098 |
| RybelsusSemaglutide | 51 | $61,192 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $60,753 |
| Repatha SureclickEvolocumab | 72 | $55,239 |
| RexultiBrexpiprazole | 22 | $48,988 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $40,504 |
| GemtesaVibegron | 69 | $36,565 |
| XareltoRivaroxaban | 33 | $34,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,696 | $377,768325 claims |
| Lilly USA, LLCMounjaro, Trulicity | $737 | $198,494168 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $231 | $126,300132 claims |
| PfizerEliquis | $14 | $117,697150 claims |
| AbbVieLinzess, Restasis | $617 | $91,210139 claims |
| AstraZenecaFarxiga | $1,734 | $79,610101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $448 | $77,528121 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $171 | $48,98822 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $78 | $36,56569 claims |
| Astellas Pharma US IncMyrbetriq | $121 | $21,25740 claims |
| MerckJanuvia | $178 | $19,90414 claims |
| BayerKerendia | $224 | $15,57914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Garner
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.